ストックスクリーナーアプリを入手
4.04
2.88%
-0.12
アフターアワーズ：
4.15
0.11
+2.72%
Zura Bio Ltd (ZURA) 最新ニュース
Zura Bio stock extends multi-month rally on strong pipeline expectations - AD HOC NEWS
Zura Bio stock extends strong rally as investors focus on pipeline and small-cap momentum - AD HOC NEWS
Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply - Yahoo Finance
Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead - Investing.com Nigeria
Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead By Investing.com - Investing.com South Africa
CABA Stock Price and Chart — NASDAQ:CABA - TradingView
Zura Bio to Participate in the Cantor Global Healthcare Conference - finance.yahoo.com
This Zura Bio Insider Increased Their Holding In The Last Year - simplywall.st
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Zura Bio (NASDAQ: ZURA) director plans 50,000-share sale after prior trades - Stock Titan
Zura Bio Releases Updated Corporate Presentation in Latest SEC Filing - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
Zura Bio (NASDAQ: ZURA) affiliate plans stock sale via option exercise - Stock Titan
Zura Bio updates corporate presentation; HS Phase 2 topline Q4 2026, SSc readout H1 2027, cash runway through 2028 - TradingView
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ZURA (ZURA) insider Someit Sidhu plans 40,000-share sale after option exercise - Stock Titan
Zura Bio Ltd SEC Filing (Aug 13, 2026) - Stock Titan
Wedbush Maintains Zura Bio(ZURA.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Zura Bio Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Guggenheim raises Zura Bio stock price target on new drug indication - Investing.com
Zura Bio Submits Q2 2026 SEC Report Highlighting Financial and Operational Status - Kalkine Media
Zura Bio Q2 Results: EPS Misses Estimate as Losses Widen 23.53% YoY - scanx.trade
Zura Bio Limited Reports Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Zura Bio Limited For: 11 August By Investing.com - Investing.com Nigeria
Zura Bio Ltd 2Q 2026: Net loss $(26.3)M, EPS $(0.21) — 10-Q Summary - TradingView
Financial update and recent changes drive Zura Bio performance - Traders Union
Zura Bio Completes Enrollment in 247-Participant Hidradenitis Study - Stock Titan
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - Yahoo Finance
Wedbush Adjusts Zura Bio Price Target to $22 From $15, Maintains Outperform Rating - Yahoo Finance
Zura Bio Ltd expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio (ZURA) Projected to Announce Earnings on Thursday - MarketBeat
1,179,715 Shares in Zura Bio Limited $ZURA Purchased by EcoR1 Capital LLC - MarketBeat
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zura Bio Ltd (ZURA) Cash Flow - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ZURA|Zura Bio Ltd|Price:5.230|Chg%:-0.060 - TradingKey
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ZURA|Zura Bio Ltd|Price:5.240|Chg%:-0.140 - TradingKey
TradingKey - TradingKey
Marlyn Teresa Mathew Net Worth (2026) - GuruFocus
William Blair Starts Zura Bio (ZURA) at Outperform - Yahoo Finance
ZURA Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus
What's Going on With Zura Bio Stock Wednesday?Zura Bio (NASDAQ:ZURA) - Benzinga
Zura Bio navigates growth path amid biotech volatility - Ad-hoc-news.de
William Blair initiates Zura Bio stock with outperform rating By Investing.com - Investing.com Nigeria
William Blair initiates Zura Bio stock with outperform rating - Investing.com
William Blair Initiates Zura Bio(ZURA.US) With Buy Rating - Moomoo
Zura Bio stock. Company profile and listing context. - Ad-hoc-news.de
Wedbush reiterates Outperform on Zura Bio, maintains $15 target - scanx.trade
Zura Bio’s Tibulizumab: First Dual BAFF & IL-17 Bispecific Antibody for Complex Autoimmune Diseases, Advancing in Phase 2 Trials – Minichart - Minichart
Jessica Chen - White & Case LLP
Zura Bio updates corporate presentation; tibulizumab Phase 2 toplines, $225.6M cash (Mar 31, 2026) - TradingView
Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors - Stock Titan
Guggenheim Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - simplywall.st
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):